Bariatric Times - August 2008 - (Page 11) Bariatric Times • August 2008 Pulmonary Perspective 11 1995;44:1126–1131. Drucker DJ: Glucagon like peptides. Diabetes. 1998;47:159–169. 13. Kieffer TJ, Habener JF: The glucagon like peptides. Endocr Rev. 1999;20:876–913. 14. Naslund E, Barkeling B, King N, et al. Energy intake and appetite are suppressed by glucagon like peptide 1 (GLP 1) in obese men. Int J Obes Relat Metab Disord. 1999;23:304–311. 15. Gutzwiller JP, Drewe J, Goke B, et al. Glucagon like peptide 1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol. 1999;276:R1541–R1544. 16. Heller RS, Kieffer TJ, Habener JF. Insulinotropic glucagonlike peptide I receptor expression in glucagon-producing cells of the rat endocrine pancreas. Diabetes. 1997;46:785–791. 17. Fehmann HC, Habener JF Functional receptors for the insulinotropic hormone glucagon-like peptide-1-(7-37) on a somatostatin secretin cell line. FEBS Lett. 1991;279:335–340. 18. Kieffer T J, Habener JF. The glucagon-like peptides. Endocrine Rev. 1999;20:876–913. 19. Redondo A, Trigo MV, Acitores A, et al. Cell signalling of the GLP-1 action in rat liver. Mol Cell Endocrinol. 2003;204:43–50. 20. Trapote MA, Clemente F, Galera C, et al. Inositol phosphoglycans are possible mediators of the glucagon-like peptide 1 (7-36) amide action in the liver. J Endocrinol Invest. 1996;19:114–118. 21. Luque MA, Gonzalez N, Marquez L, et al. Glucagon-like p eptide-1 (GLP-1) and glucose metabolism in human myocytes. J Endocrinol. 2002;173:465–473. 22. Holst JJ, Gromada J: Role of incretin hormones in the regulation of insulin secretion in diabeticand nondiabetic humans. Amer J Physiol Endocrinol Metab. 2004;287:199–206. 23. Nathan DM, Schreiber E, Fogel H, et al. Insulinotropic action of glucagonlike peptide-I(7–37) in diabetic and nondiabetic subjects. Diabetes Care. 1992;15:270–276. 24. Dumoulin V, Moro F, Barcelo A, Dakka T, Cuber JC: Peptide YY, glucagonlike peptide-1, and neurotensin responses to luminal factors in the isolated vascularly perfused rat ileum. Endocrinology. 1998;139:3780–3786. 25. Strader AD, Vahl TP, Jandacek RJ, et al. Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats. Am J Physiol Endocrinol Metab. 2005;288:447–453. 26. Gutniak M, Orskov C, Holst JJ, et al. Antidiabetogenic effect of glucagon-like peptide1 (7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med. 1992;326:1316–1322. 27. Larsen J, Hylleberg B, Ng K, Damsbo P. Glucagon-like peptide-1 infusion must be maintained for 24h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care. 2001;24:1416–1421. 28. Meneilly GS, Greig N, Tildesley H, et al. Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes. Diabetes Care. 2003;26:2835–2841. 29. Zander M, Christiansen A, Madsbad S, Holst JJ. Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetes. Diabetes Care. 2004;27:1910–1914. 30. Koopmans HS, Sclafani A, Fichtner C, et al. The effects of ileal transposition on food intake and body weight loss in VMH-obese rats. Am J Clin Nutr. 1982;35:284–331. 31. Naito H, Matsuno S. Surgical aspect of enteroinsular axis after gastrointestinal surgery with reference to incretin secretion. Pancreas. 1998;16:370–378. 32. Rubino F, Gagner M, Gentileschi P, et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg. 2004;240:236–242. 33. Mortensen K, Petersen LL, Orskov C. Colocalization of GLP 1 and GIP in human and porcine intestine. Ann NY Acad Sci. 2000;921:469–472. 34. Vilsboll T, Holst JJ. Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia. 2004;47:357–366. 35. Lewis JT, Dayanandan B, Habener JF, Kieffer TJ. Glucose dependent insulinotropic polypeptide confers early phase insulin release to oral glucose in rats: demonstration by a receptor antagonist. Endocrinology. 2000;141:3710–3716. 36. Vilsboll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia. 2002;45:1111–1119. 37. Coupaye M, Bouillot JL, Coussieu C, et al. One year changes in energy expenditure and serum 12. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. leptin following adjustable gastric banding in obese women. Obes Surg. 2005;15:827–833. Galli J, Li LS, Glaser A. Genetic analysis of noninsulin dependent diabetes mellitus in the GK rat. Nat Genet. 1996;12:31–37. Schschols AM, Creutzberg EC, Buurman WA. Plasma leptin is related to proinflammatory status and dietary intake in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160:1220–1226. Rubino F, Gagner M. Potential of surgery for curing type 2 diabetes mellitus. Ann Surg. 2002;236:554–556. Pacheco D, de Luis DA, Romero A, et al. The effects of duodenal-jejunal exclusion on hormonal regulation of glucose metabolism in GotoKakizaki rats. Am J Surg. 2007;194:221–224. Pories WJ. Why does the gastric bypass control type 2 diabetes mellitus? Obes Surg. 2002;2:303–313. Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg. 1995;222:339–350. Mason EE. Ileal transposition and enteroglucagon/ GLP-1 in obesity surgery. Obes Surg. 1999;9:223–228. Rubino F, Forgione A, Cummings DE, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006;244:741–749. Scopinaro N, Gianetta E, Civalleri D, et al. Biliopancreatic bypass for obesity: II. Initial experience in man. Br J Surg. 1979;66:618–620. Clements RH, Gonzalez QH, Long CI, et al. Hormonal changes after Roux-en Y gastric bypass for morbid obesity and the control of type-II diabetes mellitus. Am Surg. 2004;70:1–4. Kremen, AJ, Linner JH, et al. An experimental evaluation of the nutritional importance of proximal and distal small intestine. Ann Surg. 1954;140:439–448. Zundel N, Maalouf M, Caushaj P. History of bariatric surgery. In: Rosenthal R, Jones D (eds). Weight loss surgery: A Multidisciplinary Approach. Edgemont, PA: Matrix Medical Communications 2008. Sarson DL, Scopinaro N, Bloom SR. Gut hormone changes after jejunoileal (JIB) or biliopancreatic (BPB) bypass surgery for morbid obesity. Int J Obes. 1981;5:471–480. Naslund E, Backman L, Holst JJ, et al. Importance of small bowel peptides for the improved glucose metabolism 20 years after jejunoileal bypass for obesity. Obes Surg. 1998;8:253–260. Yeo C. Shackelford’s Surgery of the Alimentary Tract (6th ed). Philadelphia: Elsevier Saunders 2006. Rubino F, Marescaux J. Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg. 2004;239:1–11. MacFarlane A, Kinsman R, Read NW, et al. The ileal brake: ileal fat slows down small bowel transit and gastric emptying in man. Gut. 1983;24:471–472. de Paula AL, Antônio L, Macedo V. Laparoscopic sleeve gastrectomy with ileal interposition (“neuroendocrine brake”) pilot study of a new operation. Surg Obes Rel Dis. 2006;2:464–467. Pories WJ, Albrecht RJ. Etiology of type 2 diabetes mellitus: role of the foregut. World J Surg. 2001;25:527–531. Guidone C, Manco M. Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes. 2006;55:2025–2031. Scopinaro N, Marinari GM, Camerini GB, et al. Specific effects of biliopancreatic diversion on the major components of metabolic syndrome: a long-term follow-up study. Diabetes Care. 2005;28:2406–411. Mingrone G, Henriksen FL, Greco AV, Krogh LN. Triglyceride induced diabetes associated with familial lipoprotein lipase deficiency. Diabetes. 1999;48:1258–1263. Patriti A, Facchiano E.The enteroinsular axis and the recovery from type 2 diabetes after bariatric surgery. Obes Surg. 2004;14:840–848. ADDRESS FOR CORRESPONDENCE: Natan Zundel, MD, FACS, 17038 W. Dixie Hwy., Ste. 210, Miami Beach, FL 33160; E-mail: drnazuma99@yahoo.com. http://www.newdirectionsystem.com http://www.newdirectionsystem.com
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.